Zanubrutinib with G-CVP for untreated follicular lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (G-CVP) for people with follicular lymphoma who have not had treatment before. It aims to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have follicular lymphoma that is CD20-positive (a protein on the cancer cells) and grades 1, 2, or 3a.
- Your lymphoma must be causing symptoms like pain, organ problems, low blood counts, or large tumors.
- You must not have had any prior chemotherapy or other systemic treatment for lymphoma.
- You must be between 18 and 80 years old.
- You must have at least one tumor that can be measured on a scan (at least 1.5 cm in the lymph node or 1 cm elsewhere).
- You must be willing to follow the study plan and attend follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, zuberitamab and bendamustine, for people with a type of lymphoma called follicular lymphoma who have not had treatment before. The goal is to see if this combination is safe and effective, and then if keeping on one of the drugs alone helps keep the cancer from coming back.
This trial tests a combination of three drugs for people with previously untreated follicular lymphoma. The goal is to see if this combination helps control the lymphoma better.
This study tests a new drug combination (using two targeted medicines and an immunotherapy drug) versus a standard chemotherapy combination for people with untreated follicular lymphoma. The goal is to see if the new combo works better with fewer side effects.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, and venetoclax) for people with untreated follicular lymphoma. The goal is to see if this combination works better than standard treatments and has manageable side effects.
This trial is testing a combination of targeted drugs, including zanubrutinib, for people newly diagnosed with a fast-growing lymphoma called DLBCL. It is designed for patients with certain risk factors that make their lymphoma more aggressive, and it aims to see if these drug combinations can work better than standard treatments.
Hear when a new Follicular Lymphoma ( FL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.